The Setup

Aebi Schmidt is a Swiss specialty vehicle company — snowplows, airport de-icers, street sweepers, agricultural machines for Alpine terrain. Founded 1883. About as boring as it gets. Then in July 2025 it merged with The Shyft Group in an all-stock deal, simultaneously listing on Nasdaq.

From $33 to $11.49 in eight months. Down 65%.

The 10-K filed today reads like a crime scene. Operating cash flow collapsed 87%. Five material weaknesses in internal controls — unremediated. Leverage at 3.7x against a 3.25x covenant. Gross margins compressed. Net income down 68%. Government spending risk flagged explicitly ("frozen or refused to honor certain promised payments and subsidies to farmers"). If you stopped reading there, you'd run.

But on the same day this 10-K hit, AEBI also reported Q4 results: Adj EBITDA up 31%. Order intake up 46%. Record backlog. Net debt declining. EBITDA margins marching upward quarter after quarter — 6.9%, 7.6%, 9.0%, 9.1%. Guidance for $175-195M EBITDA in 2026, implying a forward multiple of 6.5x against peers trading at 9-16x.

The stock dropped 10% on this news.

And while the stock was cratering, seven company insiders — the CEO, the CFO, and five other officers and directors — made ten separate open-market purchases between August and December 2025. All in the $10-14 range. Zero sells.

This is the setup. The question is whether it's a setup for a recovery or a trap.

The Mechanism

Understanding WHY the stock crashed is more important than the fact that it did. The all-stock merger created 36.35 million new AEBI shares and handed them to former Shyft Group shareholders. These were people who owned an American truck body and RV chassis company. They woke up one morning holding shares in a Swiss industrial conglomerate with a controlling shareholder named Peter Spuhler, five material weaknesses, and filings denominated in a mixture of U.S. GAAP and what appears to be Swiss conservatism in risk disclosure.

They sold. Of course they sold. Index funds that held SHYF couldn't hold AEBI. Institutional mandates that prohibit material weakness names had to exit. The shareholder base didn't change gradually — it shattered and reformed.

This is technical selling, not fundamental selling. The business didn't deteriorate. The people who understand the business — the ones who run it — bought stock while everyone else was selling. That's the single most important data point in this analysis.

Cross-referencing against peers: Oshkosh (OSK) was down to RSI 14.6. Alamo Group (ALG) hit RSI 18.6. Both are similarly oversold specialty vehicle names. Neither showed coordinated insider buying. The academic literature (ScienceDirect 2024, AEA 2018, Dartmouth) confirms that opportunistic C-suite buying in undervalued, post-SPAC companies is among the strongest predictive signals for subsequent outperformance. Only 11% of post-SPAC companies ever trade above their offering price. Insiders buying into that pattern — buying, not selling — is statistically unusual.

What the Bears See (And Why They're Mostly Wrong)

Every bear argument we tested turned out to be either a sector factor or a standard post-merger pattern, not AEBI-specific distress.

OCF collapse ($68.8M to $9.0M): The $61.4M AR collection shortfall looked terrifying until we found the analog. Standard Motor Products acquired Nissens Automotive (a European aftermarket supplier) in late 2024 for $390M — nearly identical deal structure (U.S. acquirer, European target). SMP's first year showed the exact same pattern: IT control material weaknesses at the European subsidiary, working capital disruption, clean audit opinion, remediation underway. AR blowouts from billing system fragmentation in Year 1 post-acquisition are well-documented in M&A literature. Oshkosh regularly sees $435M seasonal working capital swings. AEBI's $61M swing on $1.9B revenue (3.2%) is within normal range. And Q4 data already shows recovery — net working capital down 6% quarter over quarter, net debt declining.

Five material weaknesses: Twenty-two companies in the earnings transcript corpus disclosed material weaknesses in the last two years, including CORZ, SMR, VVV, BUR, CPAY, and — again — SMP with its Nissens acquisition. Five MWs is on the high end, but the categories (IT general controls, purchase accounting, segregation of duties) are standard first-year SOX compliance issues for cross-border filers. The key signal: clean audit opinion. The auditors looked at all five weaknesses and signed off on the financials anyway. No restatements.

Government spending risk: Twenty-nine companies flagged "federal funding" uncertainty in 2025-2026 transcripts. This is a sector factor, not AEBI-specific. More importantly, Federal Signal — the closest peer in municipal equipment — just posted record revenue ($2.18B, +17%) and 45% order growth. Municipal equipment procurement is funded from local revenues (water/sewer fees, police budgets), not federal grants. The DOGE headlines are noise for this segment. Airport equipment and farm subsidies are more exposed, but these are small relative to total revenue.

Leverage at 3.7x: Updated by Q4 earnings. Net debt declined $32M in Q4 alone. Company is guiding to below 2.0x by year-end 2026. The trajectory is down, not up. Covenant stress was a real risk six months ago; the data now says it's resolving.

Original composite LR across all five bear signals: 0.56 (bearish). After cross-ticker corroboration: 1.51 (mildly bullish). Every bear signal weakened when we checked it against reality.

The Valuation Gap

This is where it gets hard to ignore.

AEBI is trading at a 35-55% discount to every single peer on forward metrics. Even the cheapest comparable (Oshkosh, itself deeply oversold) trades at nearly double AEBI's multiple. At the merger announcement, the combined entity was valued at 12.8x proforma EBITDA. It's now at 6.5x. A 50% multiple compression in eight months, during which the business grew EBITDA 34% and orders 46%.

At OSK's 9x multiple on $185M guided EBITDA, AEBI equity is worth $15.85 per share — 38% above current. At the peer average of 12x, it's $23 — a double. At FSS multiples (which would require growth re-rating), it's $32.

The market is pricing a permanent ≈40% discount to the cheapest peer. That discount is only justified if one of two things is true: (1) the integration is failing and EBITDA will miss guidance, or (2) the controlling shareholders will extract value at minority shareholders' expense. The insiders buying with their own money argues against both.

What the Market Implies vs. What We Think

Working backward from $11.49 with our scenario targets:

The market is pricing 60% probability that this is a value trap. We're at 35%. The 25 percentage point gap on the bear case is the edge — worth $2.21 per share, or 19.2%.

Seventy percent of the edge comes from the bull case. We're not just betting the stock goes up a little. We're betting the market dramatically underestimates the probability that this company re-rates to peer multiples once the post-merger selling exhausts and Q1 confirms the integration is working.

The Trade

What we're betting on: Technical selling from former Shyft shareholders is creating temporary mispricing in a business that's actually executing. Insiders with maximum information are buying. The bear signals (OCF, MWs, leverage, government spending) are standard post-merger patterns that typically resolve in 2-3 quarters, and Q4 already shows recovery.

What we're betting against: The market's 60% bear probability. We think this is anchored on first-impression fear from the messy Year 1 financials and structural selling from holders who never wanted this stock.

Factor decomposition: ≈67% of thesis variance comes from factors where we have edge (post-merger technical selling, integration execution via insider signal, coverage gap, municipal demand contrarian). ≈33% is market/sector exposure we accept without edge.

Scenarios (12 months from $11.49):

Expected value: $13.70 (+19.2%). Idiosyncratic alpha after factor adjustment: 8.4% annualized.

Sizing framework: At 8.4% idio alpha and 67% edge variance, a starter position sized for Q1 optionality makes sense — small enough to survive being early, with the thesis calling for adds if Q1 OCF recovers above $25M in May 2026. Covenant breach, restatement, or negative OCF would invalidate the thesis.

What Keeps Me Honest

The alpha isn't huge. 8.4% expected idio alpha is a real number, not a fantasy, but it's not a screamer either. What makes this worth underwriting is the asymmetry (2.5:1 upside/downside, 65% win rate) and the structural information advantage (3 analysts, $900M cap, no institutional following).

The things that could kill it:

The path is violent. 48.5% idiosyncratic volatility. No options chain to define risk. This stock moves a dollar a day. Being right on the thesis but early by a quarter means drawdowns that test conviction.

Q1 might actually be bad. Management explicitly warned: "slow start, market softness, geopolitical uncertainty." They're either sandbagging (setting a low bar to beat) or honestly telling you the first quarter is going to hurt. If Q1 OCF comes in negative again, the market's 60% bear probability starts looking prescient.

The controlling shareholders. PCS Holding at 35% with four board seats and the ability to increase their stake after July 2027. Related-party shareholder loans of $59.1M. Swiss corporation structure limits minority protections. If they decide to take this private at $12, there's not much standing in their way.

Proforma organic growth is 2%. Strip out the merger math, and the combined entity barely grew. This isn't a growth story. It's a "the market is wrong about the probability of failure" story. Those can work, but they require the market to actually change its mind, which requires catalysts and time.

The Gate

Q1 2026 earnings (May 2026) is the decision point. Everything before is positioning.

If OCF recovers above $25M and EBITDA tracks toward guidance — the integration is working, the AR blowout was temporary, and the stock re-rates. Add to full size.

If Q1 disappoints materially — the SMP/Nissens analog breaks, the recovery timeline extends, and the bear case gains credibility. Hold starter, tighten stop.

If covenant breach or restatement — thesis is dead. Exit immediately.

The insiders bought between $10 and $14. They know what Q1 looks like. They bought anyway.

Evidence